Gamal Esmat
YOU?
Author Swipe
View article: Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC Open
Background Hepatocellular carcinoma (HCC) ranks sixth amongst all cancers and is the 2nd top cause of mortality attributable to cancer. Aim of the work This study aimed to ascertain the sustained virological response (SVR) to interferon-fr…
View article: Lubiprostone Reduces Fat Content on <scp>MRI</scp>‐<scp>PDFF</scp> in Patients With <scp>MASLD</scp>: A 48‐Week Randomised Controlled Trial
Lubiprostone Reduces Fat Content on <span>MRI</span>‐<span>PDFF</span> in Patients With <span>MASLD</span>: A 48‐Week Randomised Controlled Trial Open
Background and Aims The laxative lubiprostone has been shown to decrease intestinal permeability. We aimed to assess the safety and efficacy of lubiprostone administered for 48 weeks in patients with metabolic dysfunction‐associated steato…
View article: OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix proteoglycan decorin in hepatocellular carcinoma
OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix proteoglycan decorin in hepatocellular carcinoma Open
To our knowledge, this is the first study to unveil the direct targeting of DCN by oncomiR-181a. We also highlighted that miR-181a affects targets related to cellular proliferation in HCC which may be partly mediated through inhibition of …
View article: Generic sofosbuvir and daclatasvir for treatment of hepatitis C virus infection in patients with sickle cell disease
Generic sofosbuvir and daclatasvir for treatment of hepatitis C virus infection in patients with sickle cell disease Open
Background and purpose of the study Sickle cell disease (SCD) patients are at a high risk of chronic liver disease (CLD) due to chronic viral hepatitis infection such as hepatitis C virus (HCV) infection, iron overload, and sickle cell hep…
View article: Prevalence and predictors of hepatic steatosis among HIV patients with and without chronic hepatitis C
Prevalence and predictors of hepatic steatosis among HIV patients with and without chronic hepatitis C Open
Background and purpose of the study Hepatic steatosis (HS) is a common and important histologic finding in patients with chronic hepatitis C virus (HCV) infection. However, little is known about this finding in HCV patients co-infected wit…
View article: Obesity prevalence in adults and patients with hepatitis C: results from screening a population of 50 million in Egypt
Obesity prevalence in adults and patients with hepatitis C: results from screening a population of 50 million in Egypt Open
Obesity is a global health problem and has been increasing in Egypt over the last several decades. A national population screening program for hepatitis C included screening for obesity. Here we report the outcome of body mass index (BMI) …
View article: Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs
Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs Open
Background and aims NS5A inhibitors are an important option for treating chronic HCV-GT4 patients. Retreatments after NS5A-based DAAs failure are limited. We aimed to determine the effectiveness and safety of SOF/VEL-containing regimens fo…
View article: Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region
Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region Open
Hepatocellular carcinoma (HCC) is a growing health concern projected to cross over a million cases worldwide by 2025. HCC presents a significant burden of disease in Middle East and North African (MENA) countries due to a high prevalence o…
View article: Performance of Albumin-Bilirubin (ALBI) score in comparison to other non-invasive markers in the staging of liver fibrosis in chronic HCV patients
Performance of Albumin-Bilirubin (ALBI) score in comparison to other non-invasive markers in the staging of liver fibrosis in chronic HCV patients Open
Background The prognostic ability of albumin-bilirubin score (ALBI) to assess the hepatic dysfunction in patients with hepatocellular carcinoma (HCC) was previously studied. Its role in the staging of liver fibrosis post chronic hepatitis …
View article: Effect of HCV treatment with DAAs on serum intestinal fatty acid binding protein (I-FABP) as a marker of intestinal permeability in HCV/HIV co-infected patients
Effect of HCV treatment with DAAs on serum intestinal fatty acid binding protein (I-FABP) as a marker of intestinal permeability in HCV/HIV co-infected patients Open
Background HCV and HIV co-infected patients develop cirrhosis more rapidly than HCV mono-infection. Intestinal injury and microbial translocation are postulated mechanisms for the rapid progression of cirrhosis. Aim Study the effect of HCV…
View article: Predictors of Treatment Failure with Sofosbuvir/Daclatasvir Regimen for 12 Weeks in Patients with Chronic HCV in Egypt
Predictors of Treatment Failure with Sofosbuvir/Daclatasvir Regimen for 12 Weeks in Patients with Chronic HCV in Egypt Open
Background: Hepatitis C virus HCV infection is one of the main causes of chronic liver disease worldwide, Egypt has the highest national-level HCV prevalence in the world, Sofosbuvir/ Daclatasvir (SOF/DAC) regimen widely used to treat HCV …
View article: Long-term Follow-up of Chronic Hepatitis C Patients Treated by Direct- Acting Antivirals
Long-term Follow-up of Chronic Hepatitis C Patients Treated by Direct- Acting Antivirals Open
epatitis C virus HCV infection is one of the main causes of chronic liver disease worldwide, Egypt has the highest national-level HCV prevalence in the world, and direct Acting Antivirals are widely used to treat HCV infection in Egypt. Ai…
View article: Incidence of hepatitis C virus infection among people living with HIV: An Egyptian cohort study
Incidence of hepatitis C virus infection among people living with HIV: An Egyptian cohort study Open
The demonstration of a high HCV infection incidence rate among HIV-infected patients and shows the need for screening and prevention in this population.
View article: Regulation of IGF2BP1 by miR-186 and its impact on downstream lncRNAs H19, FOXD2-AS1, and SNHG3 in HCC
Regulation of IGF2BP1 by miR-186 and its impact on downstream lncRNAs H19, FOXD2-AS1, and SNHG3 in HCC Open
miR-186 may exert tumor suppressor effects in HCC by repressing oncogenic lncRNAs H19, SNHG3, and FOXD2-AS1 through its effect on IGF2BP1.
View article: Securing wider EU commitment to the elimination of hepatitis C virus
Securing wider EU commitment to the elimination of hepatitis C virus Open
In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the…
View article: Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience
Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience Open
Background Outcome of HCV treatment with direct antiviral agents in malignant patients is questionable. The aim is to assess the safety and efficacy of DAAs in treatment of chronic HCV patients who received chemotherapy for malignancies. M…
View article: COVID-19 vaccine acceptance and associated factors among people living with HIV in the Middle East and North Africa region
COVID-19 vaccine acceptance and associated factors among people living with HIV in the Middle East and North Africa region Open
Background: Identifying coronavirus disease 2019 (COVID-19) vaccine acceptance and associated factors among people living with HIV (PLHIV) in the Middle East and North Africa region is important to meet the need for broad-scale vaccination…
View article: Effect of HCV treatment with DAAs on serum Intestinal Fatty Acid Binding Protein (I-FABP) as a marker of intestinal permeability in HCV/ HIV co- infected patients
Effect of HCV treatment with DAAs on serum Intestinal Fatty Acid Binding Protein (I-FABP) as a marker of intestinal permeability in HCV/ HIV co- infected patients Open
Background: HCV and HIV co-infected patients develop cirrhosis more rapidly than HCV mono-infection. Intestinal injury and microbial translocation are postulated mechanisms for rapid progression of cirrhosis. Aim: Study the effect of HCV t…
View article: The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry
The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry Open
Patients with preexisting chronic liver disease (CLD) may experience a substantial burden from both coronavirus 2019 (COVID‐19) infection and pandemic‐related life disruption. We assessed the impact of the COVID‐19 pandemic on patients wit…
View article: The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection Open
CMV co-infection has no impact on the response rate to DAAs. However, the CMV reactivation might have occurred after the complete eradication of HCV by DAAs.
View article: The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection Open
The co-infection of HCV/CMV may accelerate the progression of liver diseases and worsen responsiveness to IFN treatment. The Direct-acting antiviral agents (DAAs), currently approved therapy for HCV, may cause a transient change in immune …
View article: The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? Open
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease. Despite affecting an estimated 1 in 4 adults g…
View article: Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set
Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set Open
Achieving global elimination of hepatitis C virus requires a substantial scale‐up of testing. Point‐of‐care HCV viral load assays are available as an alternative to laboratory‐based assays to promote access in hard to reach or marginalized…